经典型霍奇金淋巴瘤中的程序性死亡受体1阻断疗法 - Suppr

Suppr

超能文献

PD-1 Blockade in Classic Hodgkin Lymphoma.

作者信息

Ansell Stephen M

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN.

出版信息

JCO Oncol Pract. 2021 Feb;17(2):72-73. doi: 10.1200/OP.20.01020. Epub 2021 Jan 13.

DOI:10.1200/OP.20.01020

PMID:33439697

Abstract

摘要

相似文献

PD-1 Blockade in Classic Hodgkin Lymphoma.经典型霍奇金淋巴瘤中的程序性死亡受体1阻断疗法

JCO Oncol Pract. 2021 Feb;17(2):72-73. doi: 10.1200/OP.20.01020. Epub 2021 Jan 13.

PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.PD-1/PD-L1 通路及其阻断在经典霍奇金淋巴瘤和非霍奇金大细胞淋巴瘤患者中的作用。

Curr Hematol Malig Rep. 2020 Aug;15(4):372-381. doi: 10.1007/s11899-020-00589-y.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.主要组织相容性复合体 II 类和程序性死亡配体 1 表达预测经典霍奇金淋巴瘤接受程序性死亡 1 阻断后的结局。

J Clin Oncol. 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. Epub 2018 Feb 2.

PD-1 blockade for untreated Hodgkin lymphoma.用于未经治疗的霍奇金淋巴瘤的程序性死亡受体1阻断疗法

Blood. 2021 Mar 11;137(10):1271-1272. doi: 10.1182/blood.2020009281.

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.血管免疫母细胞性T细胞淋巴瘤和霍奇金病中PD-L1阳性细胞的免疫表型分析。

BMC Res Notes. 2020 Mar 7;13(1):139. doi: 10.1186/s13104-020-04975-w.

Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy.程序性细胞死亡蛋白1（PD1）在经典型霍奇金淋巴瘤微环境中的表达在预后良好和不良的患者中相似，并且在传统化疗的系列复发过程中不会富集。

Haematologica. 2019 Jan;104(1):e42-e44. doi: 10.3324/haematol.2018.204818.

PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.PD-1和PD-L1免疫组化作为小标本活检中经典型霍奇金淋巴瘤的诊断工具

Am J Surg Pathol. 2021 Sep 1;45(9):1293-1296. doi: 10.1097/PAS.0000000000001654.

Response To: PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.回应：PD-1和PD-L1免疫组化作为小标本活检中经典型霍奇金淋巴瘤的诊断工具

Am J Surg Pathol. 2021 Sep 1;45(9):1296-1297. doi: 10.1097/PAS.0000000000001743.

PD-1 inhibitors in patients with Hodgkin lymphoma.霍奇金淋巴瘤患者中的程序性死亡受体1（PD-1）抑制剂

Eur J Cancer. 2022 Mar;164:114-116. doi: 10.1016/j.ejca.2021.06.059. Epub 2021 Aug 26.

Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.霍奇金淋巴瘤的免疫疗法：激发患者的免疫反应。

Cancer J. 2018 Sep/Oct;24(5):249-253. doi: 10.1097/PPO.0000000000000331.

引用本文的文献

Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma.复发/难治性霍奇金淋巴瘤患者异基因干细胞移植的结局

Curr Oncol. 2025 Feb 18;32(2):118. doi: 10.3390/curroncol32020118.

Pathobiological Features and Therapeutic Opportunities Linked to TNF Family Member Expression in Classic Hodgkin Lymphoma.与经典型霍奇金淋巴瘤中TNF家族成员表达相关的病理生物学特征及治疗机会

Cancers (Basel). 2024 Dec 5;16(23):4070. doi: 10.3390/cancers16234070.

Proteomic Profiling of Lymph Nodes Differentiates Classic Hodgkin Lymphoma With and Without Skeletal Involvement.淋巴结的蛋白质组学分析可区分有无骨骼受累的经典型霍奇金淋巴瘤。

Eur J Haematol. 2025 Jan;114(1):173-185. doi: 10.1111/ejh.14326. Epub 2024 Oct 11.

A New Histology-Based Prognostic Index for Aggressive T-Cell lymphoma: Preliminary Results of the "TCL Urayasu Classification".一种基于组织学的侵袭性T细胞淋巴瘤新预后指数：“TCL浦安分类”的初步结果

J Clin Med. 2024 Jun 30;13(13):3870. doi: 10.3390/jcm13133870.

Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on Therapy.浆母细胞淋巴瘤。最新综述：第2部分-聚焦治疗

Mediterr J Hematol Infect Dis. 2024 Mar 1;16(1):e2024015. doi: 10.4084/MJHID.2024.015. eCollection 2024.

Management of limited-stage Hodgkin lymphoma.局限性 Hodgkin 淋巴瘤的治疗管理。

Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):500-509. doi: 10.1182/hematology.2023000511.

Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment.突破障碍：NEK2 抑制在多发性骨髓瘤治疗中大放异彩。

Cell Rep Med. 2023 Oct 17;4(10):101237. doi: 10.1016/j.xcrm.2023.101237.

Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy response.肿瘤微环境中癌胚重编程的免疫抑制机制：对免疫治疗反应的影响。

Biochem Soc Trans. 2023 Apr 26;51(2):597-612. doi: 10.1042/BST20220157.

Incorporating novel agents into frontline treatment of Hodgkin lymphoma.将新型药物纳入霍奇金淋巴瘤的一线治疗。

Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):706-716. doi: 10.1182/hematology.2022000363.

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas.PD-1/PD-L1通路：CD30阳性大细胞淋巴瘤的一个治疗靶点。

Biomedicines. 2022 Jul 4;10(7):1587. doi: 10.3390/biomedicines10071587.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验